These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21269744)

  • 21. The role of stem-cell transplantation in chronic lymphocytic leukemia risk-adapted therapy.
    Giné E; Moreno C; Esteve J; Montserrat E
    Best Pract Res Clin Haematol; 2007 Sep; 20(3):529-43. PubMed ID: 17707838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of allogeneic stem cell transplantation on high risk chronic lymphocytic leukaemia: a single centre retrospective analysis.
    Válková V; Schwarz J; Vítek A; Marková M; Pohlreich D; Benešová K; Michalová K; Cetkovský P; Trněný M
    Hematol Oncol; 2011 Mar; 29(1):22-30. PubMed ID: 20535783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia.
    Pfitzner T; Reiser M; Barth S; Borchmann P; Schulz H; Schinköthe T; Oberhäuser F; Wessels J; Tur M; Diehl V; Engert A
    Ann Hematol; 2002 May; 81(5):258-66. PubMed ID: 12029535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR.
    Raponi S; Della Starza I; De Propris MS; Del Giudice I; Mauro FR; Marinelli M; Di Maio V; Piciocchi A; Foà R; Guarini A
    Br J Haematol; 2014 Aug; 166(3):360-8. PubMed ID: 24735016
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: possible role of graft-versus-leukemia.
    Mehta J; Powles R; Singhal S; Iveson T; Treleaven J; Catovsky D
    Bone Marrow Transplant; 1996 Mar; 17(3):371-5. PubMed ID: 8704689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical relevance of MRD in children undergoing allogeneic stem cell transplantation for ALL.
    Goulden N; Steward C
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):59-70. PubMed ID: 11987916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies.
    Díez-Campelo M; Pérez-Simón JA; Pérez J; Alcoceba M; Richtmon J; Vidriales B; San Miguel J
    Am J Hematol; 2009 Mar; 84(3):149-52. PubMed ID: 19123459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is there a role for minimal residual disease levels in the treatment of ALL patients who receive allogeneic stem cells?
    Schilham MW; Balduzzi A; Bader P;
    Bone Marrow Transplant; 2005 Mar; 35 Suppl 1():S49-52. PubMed ID: 15812531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
    Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R
    Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unmanipulated peripheral blood stem cell autograft in chronic lymphocytic leukemia: clinical findings and biological monitoring.
    Meloni G; Proia A; Mauro F; Amaranto P; Capria S; Cimino G; Cordone I; de Fabritiis P; Rapanotti C; Reato G; Vignetti M; Foa R; Mandelli F
    Haematologica; 2000 Sep; 85(9):952-60. PubMed ID: 10980634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of minimal residual disease in acute leukemia.
    van der Velden VH; Boeckx N; van Wering ER; van Dongen JJ
    J Biol Regul Homeost Agents; 2004; 18(2):146-54. PubMed ID: 15471219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy by allogeneic stem cell transplantation.
    Ringdén O
    Adv Cancer Res; 2007; 97():25-60. PubMed ID: 17419940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allogeneic stem cell transplantation for chronic myeloid leukemia.
    Barrett J
    Semin Hematol; 2003 Jan; 40(1):59-71. PubMed ID: 12563612
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Graft-versus-leukemia in chronic lymphocytic leukemia.
    Ben-Bassat I; Raanani P; Gale RP
    Bone Marrow Transplant; 2007 Apr; 39(8):441-6. PubMed ID: 17322931
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The detection and significance of minimal residual disease in acute and chronic leukemia.
    Chung NG; Buxhofer-Ausch V; Radich JP
    Tissue Antigens; 2006 Nov; 68(5):371-85. PubMed ID: 17092250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
    Bosch F; Ferrer A; Villamor N; González M; Briones J; González-Barca E; Abella E; Gardella S; Escoda L; Pérez-Ceballos E; Asensi A; Sayas MJ; Font L; Altés A; Muntañola A; Bertazzoni P; Rozman M; Aymerich M; Giné E; Montserrat E
    Clin Cancer Res; 2008 Jan; 14(1):155-61. PubMed ID: 18172266
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stem-cell transplantation in chronic lymphocytic leukemia: the time for designing randomized studies has arrived.
    Waselenko JK; Flynn JM; Byrd JC
    Semin Oncol; 1999 Feb; 26(1):48-61. PubMed ID: 10073561
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stem cell transplantation for chronic lymphocytic leukaemia.
    Paneesha S; Milligan DW
    Br J Haematol; 2005 Jan; 128(2):145-52. PubMed ID: 15638848
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical implications of minimal residual disease monitoring for stem cell transplantation after reduced intensity and nonmyeloablative conditioning.
    Shimoni A; Nagler A
    Acta Haematol; 2004; 112(1-2):93-104. PubMed ID: 15179009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
    Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
    Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.